Page last updated: 2024-11-12

tetronic 701

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tetronic 701: series of surface-active block polymers with added hydrophilic (polyoxyethylene) and hydrophobic (polyoxypropylene) side chains to ethylene-diamine; used as a drug carrier [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID20641892
CHEMBL ID3185417
SCHEMBL ID15215483
MeSH IDM0059684

Synonyms (11)

Synonym
tox21_302455
dsstox_gsid_47630
dsstox_cid_27630
NCGC00256756-01
cas-110617-70-4
dsstox_rid_82462
tetronic 701
SCHEMBL15215483
CHEMBL3185417
DTXSID10860091
6,9-bis[2-(2-hydroxyethoxy)propyl]-4,11-dimethyl-3,12-dioxa-6,9-diazatetradecane-1,14-diol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" A single intravenous administration of poloxamine-908-coated particles dramatically affected the circulation half-life and body distribution of a second subsequent dose."( A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats.
Gray, T; Moghimi, SM, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
" Their potential for the administration of drugs by different routes and the improvement of the drug bioavailability and therapeutic effect are discussed."( Poloxamine-based nanomaterials for drug delivery.
Alvarez-Lorenzo, C; Concheiro, A; Rey-Rico, A; Sosnik, A; Taboada, P, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
"Solutions of endotoxin free poloxamine 908 were injected daily intravenously to rats, and the effect on the degree of sequestration by the liver of I125 labelled, poloxamine 908-coated 60 nm polystyrene particles was investigated by studying effect of dosing regimen(s) and assessment of opsonic activity."( Activation of the mononuclear phagocyte system by poloxamine 908: its implications for targeted drug delivery.
Armstrong, TI; Davis, SS; Illum, L; Moghimi, SM, 1997
)
0.3
"After 3 or 4 days repeated dosing with poloxamine 908 (0."( Activation of the mononuclear phagocyte system by poloxamine 908: its implications for targeted drug delivery.
Armstrong, TI; Davis, SS; Illum, L; Moghimi, SM, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency26.30450.000221.22318,912.5098AID1259243; AID1259247
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.28170.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency3.31150.005428.02631,258.9301AID1346982
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency66.67090.001019.414170.9645AID743191
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency36.10510.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.50)18.7374
1990's24 (60.00)18.2507
2000's5 (12.50)29.6817
2010's10 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.96 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index6.08 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]